Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.
Enveric Biosciences Expands IP Portfolio With New U.S. Patent For Novel Carboxylated Psilocybin Derivatives Supporting Its EVM301 Series Of Drug Candidates
Claims to novel composition of matter and pharmaceutical drug formulations encompass EVM301 Series of drug candidates, targeting various difficult-to-treat mental health disorders by promoting neuroplasticity without
